Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Operating Leases (2019 - 2025)

Tvardi Therapeutics' Operating Leases history spans 7 years, with the latest figure at $85000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases fell 57.71% to $85000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $85000.0, a 57.71% decrease, with the full-year FY2025 number at $85000.0, down 57.71% from a year prior.
  • Operating Leases hit $85000.0 in Q4 2025 for Tvardi Therapeutics, down from $115000.0 in the prior quarter.
  • Over the last five years, Operating Leases for TVRD hit a ceiling of $7.3 million in Q2 2024 and a floor of $85000.0 in Q4 2025.
  • Historically, Operating Leases has averaged $2.7 million across 5 years, with a median of $1.9 million in 2021.
  • Biggest five-year swings in Operating Leases: surged 1271.23% in 2023 and later tumbled 98.02% in 2025.
  • Tracing TVRD's Operating Leases over 5 years: stood at $1.9 million in 2021, then plummeted by 74.09% to $497000.0 in 2022, then soared by 1124.95% to $6.1 million in 2023, then crashed by 96.7% to $201000.0 in 2024, then crashed by 57.71% to $85000.0 in 2025.
  • Business Quant data shows Operating Leases for TVRD at $85000.0 in Q4 2025, $115000.0 in Q3 2025, and $145000.0 in Q2 2025.